These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37013843)

  • 21. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
    Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
    J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
    Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
    Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cell therapy in cancer treatment; the state-of-the-art.
    Sadeghzadeh M; Bornehdeli S; Mohahammadrezakhani H; Abolghasemi M; Poursaei E; Asadi M; Zafari V; Aghebati-Maleki L; Shanehbandi D
    Life Sci; 2020 Aug; 254():117580. PubMed ID: 32205087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of dendritic cell immunotherapy by recalling antigens for hepatocellular carcinoma in mice.
    Lee WC; Cheng CH; Lee CF; Hsu HY; Hsu PY; Wu TJ; Chan KM
    Immunotherapy; 2022 Oct; 14(15):1225-1236. PubMed ID: 36097695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma.
    Fedorova L; Mudry P; Pilatova K; Selingerova I; Merhautova J; Rehak Z; Valik D; Hlavackova E; Cerna D; Faberova L; Mazanek P; Pavelka Z; Demlova R; Sterba J; Zdrazilova-Dubska L
    Front Oncol; 2019; 9():1169. PubMed ID: 31799177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
    Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S
    Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic dendritic cell-based cancer vaccines: the state of the art.
    Strioga MM; Felzmann T; Powell DJ; Ostapenko V; Dobrovolskiene NT; Matuskova M; Michalek J; Schijns VE
    Crit Rev Immunol; 2013; 33(6):489-547. PubMed ID: 24266347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell immunotherapy.
    Sabado RL; Bhardwaj N
    Ann N Y Acad Sci; 2013 May; 1284():31-45. PubMed ID: 23651191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of dendritic cells in cancer.
    Lee YS; Radford KJ
    Int Rev Cell Mol Biol; 2019; 348():123-178. PubMed ID: 31810552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy.
    Jugniot N; Dahl JJ; Paulmurugan R
    J Exp Clin Cancer Res; 2022 Oct; 41(1):299. PubMed ID: 36224614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects].
    Rossowska J; Pajtasz-Piasecka E
    Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.
    Tyagi RK; Mangal S; Garg N; Sharma PK
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):97-114. PubMed ID: 19105710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
    Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
    Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside.
    Ghorbaninezhad F; Asadzadeh Z; Masoumi J; Mokhtarzadeh A; Kazemi T; Aghebati-Maleki L; Shotorbani SS; Shadbad MA; Baghbanzadeh A; Hemmat N; Bakhshivand M; Baradaran B
    Life Sci; 2022 May; 297():120466. PubMed ID: 35271882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities.
    Fu C; Ma T; Zhou L; Mi QS; Jiang A
    Immunol Invest; 2022 Nov; 51(8):2133-2158. PubMed ID: 35946383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
    Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
    J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
    Flores I; Hevia D; Tittarelli A; Soto D; Rojas-Sepúlveda D; Pereda C; Tempio F; Fuentes C; Falcón-Beas C; Gatica J; Falcón-Beas F; Galindo M; Salazar-Onfray F; González FE; López MN
    J Immunol Res; 2019; 2019():9631515. PubMed ID: 31886313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
    Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
    J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.